Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Bionano Genomics Q3 2026 Results: Net Loss of $6.45M, Loss Narrows

Bionano Genomics reported total revenue of $8.28 million for the third quarter of 2026, a 12% increase year-over-year, while narrowing its quarterly net loss to $6.45 million compared to $8.50 million in 2025. The company's cash position remains tight, with total cash, cash equivalents, and investments decreasing significantly from $19.27 million at the end of 2025 to $8.17 million as of September 30, 2026.

Watch the Bionano Genomics, Inc. earnings callFull call on the ALFA USA YouTube channel
Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue8.37.4
Profit before tax-6.4-8.5
Net income-6.5-8.5
EPS (diluted, $ a share)$-0.54$-1.59

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year+12.3%
Operating margin-79.0%
Source

10-Q filed with the SEC, NASDAQ: BNGO. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Bionano Genomics, Inc.: key numbers

Share price
$0.9400Close, Nov 16
Market cap
$13.1M
Shares outstanding
13.99MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Laboratory Analytical InstrumentsSIC 3826

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Bionano Genomics, Inc.

All →
4:04 PM ET 8-K
Financial Results

Bionano Genomics Financial Results

Bionano Genomics reported Q3 2026 revenue of $8.3 million, a 12% increase year-over-year, driven by a 24% rise in consumables revenue. The company reiterated its full-year 2026 revenue guidance of $31 million to $33 million and highlighted progress in the clinical adoption of its optical genome mapping (OGM) technology.

Term
Q3 2026

“Our third quarter results reflect the momentum building across our business and the broader genomics community, further accelerating the adoption of optical genome mapping (OGM) in clinical and commercial settings.”

Al Luderer, Ph.D., chairman and interim chief executive officer

“Coverage and regulatory progress this quarter helped build a clearer reimbursement pathway for OGM-based testing, which we expect to support broader clinical adoption over time.”

Al Luderer, Ph.D., chairman and interim chief executive officer
8:31 AM ET 8-K
Investor Presentation

Bionano Genomics Investor Presentation

Bionano Genomics Chairman and Interim CEO Al Luderer is presenting at the H.C. Wainwright 28th Annual Global Investment Conference on September 14, 2026. The company filed its conference presentation deck as an exhibit, which includes updates on its business strategy, optical genome mapping (OGM) adoption, and cost-saving initiatives. The presentation also addresses the company's focus on extending its cash runway and reaching a pathway to profitability.

Counterparty
H.C. Wainwright

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.